Marksans Pharma Statistics

Total Valuation

Marksans Pharma has a market cap or net worth of INR 133.09 billion. The enterprise value is 128.59 billion.

Market Cap	133.09B
Enterprise Value	128.59B

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	Sep 17, 2024

Share Statistics

Marksans Pharma has 453.16 million shares outstanding. The number of shares has increased by 3.16% in one year.

Current Share Class	n/a
Shares Outstanding	453.16M
Shares Change (YoY)	+3.16%
Shares Change (QoQ)	+0.28%
Owned by Insiders (%)	43.87%
Owned by Institutions (%)	12.47%
Float	204.31M

Valuation Ratios

The trailing PE ratio is 38.39 and the forward PE ratio is 29.99. Marksans Pharma's PEG ratio is 1.25.

PE Ratio	38.39
Forward PE	29.99
PS Ratio	5.60
PB Ratio	5.85
P/TBV Ratio	6.14
P/FCF Ratio	255.88
P/OCF Ratio	n/a
PEG Ratio	1.25

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 25.39, with an EV/FCF ratio of 247.22.

EV / Earnings	37.06
EV / Sales	5.41
EV / EBITDA	25.39
EV / EBIT	30.35
EV / FCF	247.22

Financial Position

The company has a current ratio of 4.68, with a Debt / Equity ratio of 0.09.

Current Ratio	4.68
Quick Ratio	2.79
Debt / Equity	0.09
Debt / EBITDA	0.39
Debt / FCF	3.81
Interest Coverage	31.25

Financial Efficiency

Return on equity (ROE) is 16.54% and return on invested capital (ROIC) is 11.74%.

Return on Equity (ROE)	16.54%
Return on Assets (ROA)	10.14%
Return on Capital (ROIC)	11.74%
Revenue Per Employee	20.85M
Profits Per Employee	3.04M
Employee Count	1,141
Asset Turnover	0.91
Inventory Turnover	1.70

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +83.51% in the last 52 weeks. The beta is 1.65, so Marksans Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.65
52-Week Price Change	+83.51%
50-Day Moving Average	305.94
200-Day Moving Average	222.77
Relative Strength Index (RSI)	37.86
Average Volume (20 Days)	2,156,666

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Marksans Pharma had revenue of INR 23.79 billion and earned 3.47 billion in profits. Earnings per share was 7.65.

Revenue	23.79B
Gross Profit	12.85B
Operating Income	4.24B
Pretax Income	4.58B
Net Income	3.47B
EBITDA	4.82B
EBIT	4.24B
Earnings Per Share (EPS)	7.65

Full Income Statement

Balance Sheet

The company has 6.72 billion in cash and 1.98 billion in debt, giving a net cash position of 4.74 billion or 10.45 per share.

Cash & Cash Equivalents	6.72B
Total Debt	1.98B
Net Cash	4.74B
Net Cash Per Share	10.45
Equity (Book Value)	23.05B
Book Value Per Share	50.24
Working Capital	16.34B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.17 billion and capital expenditures -1.65 billion, giving a free cash flow of 520.15 million.

Operating Cash Flow	2.17B
Capital Expenditures	-1.65B
Free Cash Flow	520.15M
FCF Per Share	1.15

Full Cash Flow Statement

Margins

Gross margin is 54.01%, with operating and profit margins of 17.82% and 14.59%.

Gross Margin	54.01%
Operating Margin	17.82%
Pretax Margin	19.24%
Profit Margin	14.59%
EBITDA Margin	20.26%
EBIT Margin	17.82%
FCF Margin	2.19%

Dividends & Yields

This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.20%.

Dividend Per Share	0.60
Dividend Yield	0.20%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	7.84%
Buyback Yield	-3.16%
Shareholder Yield	-2.95%
Earnings Yield	2.60%
FCF Yield	0.39%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a